Trade Mark Journal No.2021/053 31 December 2021
WO0000001630189 (5,42)
Office of origin: United States of America
Date of International Registration:2 November 2021
Date of designation in the UK:
2 November 2021

International priority date claimed: 19 May 2021
(United States of America)
(90722349)
- Class 5
- Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer.
- Class 42
- Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development.
Crispr Therapeutics AG
Representative: Tiffany D. Gehrke Marshall, Gerstein & Borun LLP, 233 South Wacker Drive, 6300 Willis Tower, Chicago IL 60606, UNITED STATES OF AMERICA